An in silico epitope-based peptide vaccine design against the 2019-nCoV

The reason for this is because the antibodies which are of higher molecular weight stop the antigens from gaining access to their intracellular targets through the crossing of the cell membrane. [...]cell surface MHC-I-binding antibodies can be generated (major histocompatibility complex class I) [5...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Journal of Medical Human Genetics 2020-07, Vol.21 (1), p.35-5
Main Authors: Durojaye, Olanrewaju Ayodeji, Mushiana, Talifhani, Cosmas, Samuel, Ibiang, Glory Omini, Ibiang, Mercy Omini
Format: Article
Language:English
Subjects:
Amino acids
Antibodies
Antigenic determinants
Antigens
Cells
Coronaviruses
Correspondence
COVID-19
Design
Epitopes
Flexibility
Genetics
Genomes
Ligands
Medical research
Peptides
Proteins
Respiratory diseases
Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The reason for this is because the antibodies which are of higher molecular weight stop the antigens from gaining access to their intracellular targets through the crossing of the cell membrane. [...]cell surface MHC-I-binding antibodies can be generated (major histocompatibility complex class I) [5]. With reference to previous virus related in-silico vaccine design studies [6, 7], we designed a new potential vaccine candidate using the main proteinase of the 2019-nCoV as the target protein. Acknowledgements We appreciate the leadership of the Laboratory of Cellular Dynamics (LCD), University of Science and Technology of China for the all-round support and academic advisory role.
ISSN:1110-8630
2090-2441
DOI:10.1186/s43042-020-00071-7